GlassScriptPhysician profile
Sonia Lysette Robinson
NPI 1538899810
$4,737.97
in general payments reported to CMS, 2019-2025
24 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.04 · 2023: $1,822 · 2024: $1,650 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,708 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,708.06 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $772.38 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $647.76 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $630.10 | 2022-2025 | Fanapt, Hetlioz, Ponvory |
| Janssen Pharmaceuticals, INC | $602.71 | 2023-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $536.05 | 2023-2025 | Caplyta |
| Alkermes, INC. | $401.19 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $344.22 | 2023-2025 | Ingrezza |
| Medtronic, INC. | $130.06 | 2023 | Intellis Adaptivestim |
| Lundbeck LLC | $122.18 | 2023-2025 | Rexulti |
| Indivior INC. | $104.45 | 2023-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $90.80 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $55.08 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $52.55 | 2024-2025 | Auvelity |
| Noven Therapeutics, LLC | $38.64 | 2023-2024 | Secuado |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.40 | 2023 | Relistor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $28.52 | 2023-2024 | Loreev Xr |
| Orexo US, INC. | $27.79 | 2024-2025 | Zubsolv |
| Corium, LLC | $22.58 | 2023 | Azstarys |
| Luye Pharma (USA) LTD. | $18.47 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $17.13 | 2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $17.10 | 2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $15.65 | 2025 | Qelbree |
| Tris Pharma INC | $15.44 | 2023 | Dyanavel Xr |
| Pfizer INC. | $12.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.